Compare THFF & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THFF | ACHV |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.8M | 726.5M |
| IPO Year | 1995 | 2018 |
| Metric | THFF | ACHV |
|---|---|---|
| Price | $76.07 | $6.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $85.33 | $14.15 |
| AVG Volume (30 Days) | 132.0K | ★ 1.3M |
| Earning Date | 10-27-2026 | 11-17-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 67.00 | N/A |
| EPS | ★ 5.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.67 | N/A |
| Revenue Next Year | $16.17 | N/A |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.76 | $2.62 |
| 52 Week High | $84.17 | $8.64 |
| Indicator | THFF | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 45.05 |
| Support Level | $74.32 | $5.96 |
| Resistance Level | $78.70 | $6.64 |
| Average True Range (ATR) | 1.96 | 0.41 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 33.52 | 35.10 |
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.